-
2
-
-
34347266509
-
Changes in causes of death in systemic sclerosis, 1972-2002
-
DOI 10.1136/ard.2006.066068
-
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
-
(2007)
Annals of the Rheumatic Diseases
, vol.66
, Issue.7
, pp. 940-944
-
-
Steen, V.D.1
Medsger, T.A.2
-
3
-
-
33745227399
-
Cyclophosphamide versus placebo in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
-
(2006)
N Engl J Med
, vol.354
, pp. 2655-2666
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
Goldin, J.4
Roth, M.D.5
Furst, D.E.6
-
4
-
-
36249001195
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
-
DOI 10.1164/rccm.200702-326OC
-
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34. (Pubitemid 350127847)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.10
, pp. 1026-1034
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
Roth, M.D.4
Furst, D.E.5
Silver, R.M.6
Goldin, J.7
Arriola, E.8
Strange, C.9
Bolster, M.B.10
Seibold, J.R.11
Riley, D.J.12
Hsu, V.M.13
Varga, J.14
Schraufnagel, D.15
Theodore, A.16
Simms, R.17
Wise, R.18
Wigley, F.19
White, B.20
Steen, V.21
Read, C.22
Mayes, M.23
Parsley, E.24
Mubarak, K.25
Connolly, M.K.26
Golden, J.27
Olman, M.28
Fessler, B.29
Rothfield, N.30
Metersky, M.31
Khanna, D.32
Li, N.33
Li, G.34
more..
-
5
-
-
55749093240
-
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
-
Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10:R124.
-
(2008)
Arthritis Res Ther
, vol.10
-
-
Nannini, C.1
West, C.P.2
Erwin, P.J.3
Matteson, E.L.4
-
6
-
-
77956955777
-
The efficacy of treatment for systemic sclerosis interstitial lung disease: Results from a meta-analysis
-
Broad K, Pope JE. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis. Med Sci Monit 2010;16:RA187-90.
-
(2010)
Med Sci Monit
, vol.16
-
-
Broad, K.1
Pope, J.E.2
-
7
-
-
57049161521
-
Oral cyclophosphamide for active scleroderma lung disease: A decision analysis
-
Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH. Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making 2008;28:926-37.
-
(2008)
Med Decis Making
, vol.28
, pp. 926-937
-
-
Khanna, D.1
Furst, D.E.2
Clements, P.J.3
Tashkin, D.P.4
Eckman, M.H.5
-
8
-
-
65549124538
-
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials
-
Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009;11:111-9.
-
(2009)
Curr Rheumatol Rep
, vol.11
, pp. 111-119
-
-
Au, K.1
Khanna, D.2
Clements, P.J.3
Furst, D.E.4
Tashkin, D.P.5
-
9
-
-
0026954366
-
Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts
-
Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol 1992;7:492-9.
-
(1992)
Am J Respir Cell Mol Biol
, vol.7
, pp. 492-499
-
-
Peacock, A.J.1
Dawes, K.E.2
Shock, A.3
Gray, A.J.4
Reeves, J.T.5
Laurent, G.J.6
-
10
-
-
0037149718
-
Bosentan therapy for pulmonary arterial hypertension
-
DOI 10.1056/NEJMoa012212
-
Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.12
, pp. 896-903
-
-
Rubin, L.J.1
Badesch, D.B.2
Barst, R.J.3
Galie, N.4
Black, C.M.5
Keogh, A.6
Pulido, T.7
Frost, A.8
Roux, S.9
Leconte, I.10
Landzberg, M.11
Simonneau, G.12
-
11
-
-
50249155984
-
Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases
-
Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-8.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1222-1228
-
-
Denton, C.P.1
Pope, J.E.2
Peter, H.H.3
Gabrielli, A.4
Boonstra, A.5
Van Den Hoogen, F.H.6
-
12
-
-
0035095109
-
Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1
-
DOI 10.1046/j.1523-1747.2001.01256.x
-
Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, et al. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:417-25. (Pubitemid 32202907)
-
(2001)
Journal of Investigative Dermatology
, vol.116
, Issue.3
, pp. 417-425
-
-
Shi-Wen, X.1
Denton, C.P.2
Dashwood, M.R.3
Holmes, A.M.4
Bou-Gharios, G.5
Pearson, J.D.6
Black, C.M.7
Abraham, D.J.8
-
13
-
-
77649147853
-
Endothelin-1 contributes to the effect of transforming growth factor-β1 on wound repair and skin fibrosis
-
Lagares D, García-Fernández RA, Jiménez CL, Magán-Marchal N, Busnadiego O, Lamas S, et al. Endothelin-1 contributes to the effect of transforming growth factor-β1 on wound repair and skin fibrosis. Arthritis Rheum 2010;62:878-89.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 878-889
-
-
Lagares, D.1
García-Fernández, R.A.2
Jiménez, C.L.3
Magán-Marchal, N.4
Busnadiego, O.5
Lamas, S.6
-
14
-
-
0035674701
-
Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases
-
DOI 10.1007/s004080000058
-
Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179:163-74. (Pubitemid 34033112)
-
(2001)
Lung
, vol.179
, Issue.3
, pp. 163-174
-
-
Reichenberger, F.1
Schauer, J.2
Kellner, K.3
Sack, U.4
Stiehl, P.5
Winkler, J.6
-
15
-
-
0030755489
-
Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
-
Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156:600-8. (Pubitemid 27352001)
-
(1997)
American Journal of Respiratory and Critical Care Medicine
, vol.156
, Issue.2 I
, pp. 600-608
-
-
Park, S.-H.1
Saleh, D.2
Giaid, A.3
Michel, R.P.4
-
16
-
-
37849012578
-
BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
-
King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, De Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
-
(2008)
Am J Respir Crit Care Med
, vol.177
, pp. 75-81
-
-
King Jr., T.E.1
Behr, J.2
Brown, K.K.3
Du Bois, R.M.4
Lancaster, L.5
De Andrade, J.A.6
-
17
-
-
77954222367
-
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis
-
Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-8.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 2101-2108
-
-
Seibold, J.R.1
Denton, C.P.2
Furst, D.E.3
Guillevin, L.4
Rubin, L.J.5
Wells, A.6
-
18
-
-
0018887574
-
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
-
Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90. (Pubitemid 10101764)
-
(1980)
Arthritis and Rheumatism
, vol.23
, Issue.5
, pp. 581-590
-
-
Masi, A.T.1
Rodnan, G.P.2
Medsger, T.A.3
-
19
-
-
0000205989
-
Systemic sclerosis (scleroderma): Clinical aspects
-
Koopman WJ, editor. 13th ed. Baltimore: Williams & Wilkins
-
Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 13th ed. Baltimore: Williams & Wilkins; 1997:1433-64.
-
(1997)
Arthritis and Allied Conditions
, pp. 1433-1464
-
-
Medsger Jr., T.A.1
-
20
-
-
70049112901
-
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
-
Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
-
(2009)
Eur Heart J
, vol.30
, pp. 2493-2537
-
-
Galiè, N.1
Hoeper, M.M.2
Humbert, M.3
Torbicki, A.4
Vachiery, J.L.5
Barbera, J.A.6
-
21
-
-
49449107888
-
High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease
-
Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008;134:358-67.
-
(2008)
Chest
, vol.134
, pp. 358-367
-
-
Goldin, J.G.1
Lynch, D.A.2
Strollo, D.C.3
Suh, R.D.4
Schraufnagel, D.E.5
Clements, P.J.6
-
22
-
-
44449152061
-
Interstitial lung disease in systemic sclerosis: A simple staging system
-
DOI 10.1164/rccm.200706-877OC
-
Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54. (Pubitemid 351860934)
-
(2008)
American Journal of Respiratory and Critical Care Medicine
, vol.177
, Issue.11
, pp. 1248-1254
-
-
Goh, N.S.L.1
Desai, S.R.2
Veeraraghavan, S.3
Hansell, D.M.4
Copley, S.J.5
Maher, T.M.6
Corte, T.J.7
Sander, C.R.8
Ratoff, J.9
Devaraj, A.10
Bozovic, G.11
Denton, C.P.12
Black, C.M.13
Du, B.R.M.14
Wells, A.U.15
-
23
-
-
0036746069
-
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon
-
Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2410-2420
-
-
Merkel, P.A.1
Herlyn, K.2
Martin, R.W.3
Anderson, J.J.4
Mayes, M.D.5
Bell, P.6
-
24
-
-
0030829260
-
The value of the Health Assessment Questionnaire and special patient- generated scales to demonstrate change in systemic sclerosis patients over time
-
DOI 10.1002/art.1780401110
-
Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91. (Pubitemid 27494658)
-
(1997)
Arthritis and Rheumatism
, vol.40
, Issue.11
, pp. 1984-1991
-
-
Steen, V.D.1
Medsger Jr., T.A.2
-
25
-
-
0037981259
-
Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis
-
Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, et al. Evaluation of functional disability using the Health Assessment Questionnaire in Japanese patients with systemic sclerosis. J Rheumatol 2003;30:1253-8. (Pubitemid 36666350)
-
(2003)
Journal of Rheumatology
, vol.30
, Issue.6
, pp. 1253-1258
-
-
Kuwana, M.1
Sato, S.2
Kikuchi, K.3
Kawaguchi, Y.4
Fujisaku, A.5
Misaki, Y.6
Hatamochi, A.7
Kondo, H.8
Takehara, K.9
-
26
-
-
0027979362
-
Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis
-
Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83. (Pubitemid 24027696)
-
(1994)
Arthritis and Rheumatism
, vol.37
, Issue.1
, pp. 75-83
-
-
Kuwana, M.1
Kaburaki, J.2
Okano, Y.3
Tojo, T.4
Homma, M.5
-
27
-
-
0028360565
-
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
-
Wells AU, Cullinan P, Hansell DM, Rubens MB, Black CM, Newman-Taylor AJ, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149:1583-90. (Pubitemid 24175979)
-
(1994)
American Journal of Respiratory and Critical Care Medicine
, vol.149
, Issue.6
, pp. 1583-1590
-
-
Wells, A.U.1
Cullinan, P.2
Hansell, D.M.3
Rubens, M.B.4
Black, C.M.5
Newman-Taylor, A.J.6
Du, B.R.M.7
-
28
-
-
0344980376
-
A disease severity scale for systemic sclerosis: Development and testing
-
Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67. (Pubitemid 29487010)
-
(1999)
Journal of Rheumatology
, vol.26
, Issue.10
, pp. 2159-2167
-
-
Medsger Jr., T.A.1
Silman, A.J.2
Steen, V.D.3
Black, C.M.4
Akesson, A.5
Bacon, P.A.6
Harris, C.A.7
Jablonska, S.8
Jayson, M.I.V.9
Jimenez, S.A.10
Krieg, T.11
Leroy, E.C.12
Maddison, P.J.13
Russell, M.L.14
Schachter, R.K.15
Wollheim, F.A.16
Zacharaie, H.17
-
29
-
-
59649103901
-
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease
-
Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 569-577
-
-
Mathai, S.C.1
Hummers, L.K.2
Champion, H.C.3
Wigley, F.M.4
Zaiman, A.5
Hassoun, P.M.6
-
30
-
-
80053539331
-
Serious complications and mortality among 158 patients with systemic sclerosis (SSc) in the Scleroderma Lung Study (SLS) followed for up to 9 years
-
abstract
-
Furst DE, Khanna D, Clements PJ, Sullivan K, Tashkin DP. Serious complications and mortality among 158 patients with systemic sclerosis (SSc) in the Scleroderma Lung Study (SLS) followed for up to 9 years [abstract]. Arthritis Rheum 2010;62 Suppl:2194.
-
(2010)
Arthritis Rheum
, vol.62
, Issue.SUPPL.
, pp. 2194
-
-
Furst, D.E.1
Khanna, D.2
Clements, P.J.3
Sullivan, K.4
Tashkin, D.P.5
-
31
-
-
79551625509
-
Endothelin receptor antagonists as disease modifiers in systemic sclerosis
-
Shetty N, Derk CT. Endothelin receptor antagonists as disease modifiers in systemic sclerosis. Inflamm Allergy Drug Targets 2011;10:19-26.
-
(2011)
Inflamm Allergy Drug Targets
, vol.10
, pp. 19-26
-
-
Shetty, N.1
Derk, C.T.2
-
32
-
-
10444270963
-
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
-
DOI 10.1002/art.20676
-
Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93. (Pubitemid 39643947)
-
(2004)
Arthritis and Rheumatism
, vol.50
, Issue.12
, pp. 3985-3993
-
-
Korn, J.H.1
Mayes, M.2
Matucci, C.M.3
Rainisio, M.4
Pope, J.5
Hachulla, E.6
Rich, E.7
Carpentier, P.8
Molitor, J.9
Seibold, J.R.10
Hsu, V.11
Guillevin, L.12
Chatterjee, S.13
Peter, H.H.14
Coppock, J.15
Herrick, A.16
Merkel, P.A.17
Simms, R.18
Denton, C.P.19
Furst, D.20
Nguyen, N.21
Gaitonde, M.22
Black, C.23
more..
-
33
-
-
78650678451
-
Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
-
Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 32-38
-
-
Matucci-Cerinic, M.1
Denton, C.P.2
Furst, D.E.3
Mayes, M.D.4
Hsu, V.M.5
Carpentier, P.6
-
34
-
-
77954186593
-
Effect of bosentan on skin fibrosis in patients with systemic sclerosis: A prospective, open-label, non-comparative trial
-
Kuhn A, Haust M, Ruland V, Weber R, Verde P, Felder G, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology 2010;5:1-10.
-
(2010)
Rheumatology
, vol.5
, pp. 1-10
-
-
Kuhn, A.1
Haust, M.2
Ruland, V.3
Weber, R.4
Verde, P.5
Felder, G.6
-
35
-
-
79953012052
-
Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: An open-label, observational, retrospective study
-
Giordano N, Puccetti L, Papakostas P, Di Pietra N, Bruni F, Pasqui AL, et al. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int J Immunopathol Pharmacol 2010;23:1185-94.
-
(2010)
Int J Immunopathol Pharmacol
, vol.23
, pp. 1185-1194
-
-
Giordano, N.1
Puccetti, L.2
Papakostas, P.3
Di Pietra, N.4
Bruni, F.5
Pasqui, A.L.6
|